Microbiota Transfer Therapy for Adults With Autism Spectrum Disorder (ASD) Who Have Gastrointestinal Disorders
Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
This is a clinical trial of Microbiota Transplant Therapy (MTT) for adults with autism
spectrum disorders (ASD) who have gastrointestinal problems.
Previous research has shown that individuals with ASD have a low diversity of gut bacteria,
and low diversity is generally associated with poor gastrointestinal (GI) health. We
previously found that MTT therapy for children with ASD and GI symptoms was helpful in
reducing their GI symptoms, reducing their ASD symptoms, and increasing their diversity of
gut bacteria.
This clinical trial will investigate the hypothesis that MTT therapy will be helpful for
adults with ASD who have GI symptoms.